191170-76-0

Basic information

• Product Name: BENZYL 4-BROMOPHENETHYLCARBAMATE
• Synonyms: BENZYL 4-BROMOPHENETHYLCARBAMATE;WIUKEHNGQSSRHQ-UHFFFAOYSA-N
• CAS NO: 191170-76-0
• Molecular Formula: C₁₆H₁₆BrNO₂
• Molecular Weight: 334.21
• Mol File: 191170-76-0.mol

Chemical Properties

• Boiling Point: 473.7±38.0 °C(Predicted)
• Appearance: /
• Density: 1.367±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.38±0.46(Predicted)
• CAS DataBase Reference: BENZYL 4-BROMOPHENETHYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZYL 4-BROMOPHENETHYLCARBAMATE(191170-76-0)
• EPA Substance Registry System: BENZYL 4-BROMOPHENETHYLCARBAMATE(191170-76-0)

Safety Data

• Hazardous Substances Data: 191170-76-0(Hazardous Substances Data)

Upstream product

• 39260-89-4 2-(4-bromophenyl)-1-aminoethane hydrochloride 
• 501-53-1 benzyl chloroformate 
• 73918-56-6 4-Bromophenethylamine 
• 100-51-6 benzyl alcohol 
• 4654-39-1 4-bromophenethanol 
• 439585-11-2 N-[[[(benzyloxy)carbonyl]azanide]sulfonyl]-N,N-diethylethylammonium 

Downstream Products

• 132224-93-2 [(4-cyanophenyl)methyl]methanamine 
• 625127-09-5 benzyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 2126812-29-9 benzyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl)carbamate 

Relevant articles and documents

TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS

The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyp

THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula (I), where R1, R2, R3, R4, R5, R5', R6, R7, X, m, and n are described herein.

THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R1, R2, R3, R4, R4', R5, R6, X, and n are described herein.

INHIBITION OF BACTERIAL BIOFILMS WITH ARYL CARBAMATES

Disclosure is provided for carbamate compounds that prevent, remove and/or inhibit the formation of biofilms, compositions including these compounds, devices including these compounds, and methods of using the same.

CCR10 ANTAGONISTS

The invention relates to a compound of formula (I) or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.

A novel, one-step method for the conversion of primary alcohols into carbamate-protected amines

A novel process for the one-step conversion of primary alcohols into carbamate-protected amines has been developed using a modified Burgess reagent. Although this letter mainly focuses on the conversion of alcohols into the corresponding Cbz-protected amines, the potential for extending this process to a wide range of carbamates has also been demonstrated. A detailed catalytic cycle has been proposed. While exploring the scope of this new reagent, an N-aryl piperidine to an N-aryl pyrrolidine rearrangement has been observed and rationalized.